Literature DB >> 16501921

[Treatment of toxic epidermal necrolysis. Experience with 9 patients with consideration of intravenous immunoglobulin].

P Spornraft-Ragaller1, H Theilen, G S Gottschlich, M Ragaller.   

Abstract

Toxic epidermal necrolysis (TEN) is the maximal variant of severe bullous drug reactions with a high mortality rate of 30-40%. Treatment should be interdisciplinary and is best provided in an intensive care setting. Since no specific therapy has been established, supportive intensive care and topical treatment are of crucial importance. Between 1995 and 2005, nine patients with TEN were treated in the anesthesiology intensive care unit in cooperation with dermatology in the University Hospital of Dresden. All patients initially received corticosteroids and five patients were additionally treated with intravenous immunoglobulins (IVIG). The overall mortality of 33% was underestimated by the SAPS II-Score, whereas it was overestimated by the TEN-specific SCORTEN. In more severely affected patients, other scoring systems in addition to SCORTEN should be used for prediction of prognosis and evaluation of therapy. The mortality rate of our IVIG treated patients was 20% vs. 50% compared to the non-IVIG-group. However, due to the small number of patients and contradictory results in the literature, IVIG cannot be generally recommended for the treatment of TEN, but should be considered in early stages of the disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16501921     DOI: 10.1007/s00105-006-1104-0

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  29 in total

1.  Medical genetics: a marker for Stevens-Johnson syndrome.

Authors:  Wen-Hung Chung; Shuen-Iu Hung; Hong-Shang Hong; Mo-Song Hsih; Li-Cheng Yang; Hsin-Chun Ho; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal:  Nature       Date:  2004-04-01       Impact factor: 49.962

Review 2.  Toxic epidermal necrolysis (Lyell syndrome).

Authors:  J C Roujeau; O Chosidow; P Saiag; J C Guillaume
Journal:  J Am Acad Dermatol       Date:  1990-12       Impact factor: 11.527

3.  Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry.

Authors:  B Rzany; M Mockenhaupt; S Baur; W Schröder; U Stocker; J Mueller; N Holländer; R Bruppacher; E Schöpf
Journal:  J Clin Epidemiol       Date:  1996-07       Impact factor: 6.437

4.  Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids.

Authors:  P H Halebian; V J Corder; M R Madden; J L Finklestein; G T Shires
Journal:  Ann Surg       Date:  1986-11       Impact factor: 12.969

5.  Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience.

Authors:  M Stella; P Cassano; D Bollero; A Clemente; G Giorio
Journal:  Dermatology       Date:  2001       Impact factor: 5.366

6.  Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?

Authors:  I Garcia-Doval; L LeCleach; H Bocquet; X L Otero; J C Roujeau
Journal:  Arch Dermatol       Date:  2000-03

Review 7.  Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome.

Authors:  Pierre-Dominique Ghislain; Jean-Claude Roujeau
Journal:  Dermatol Online J       Date:  2002-06

8.  Toxic epidermal necrolysis: does immunoglobulin make a difference?

Authors:  K M Brown; G M Silver; M Halerz; P Walaszek; A Sandroni; Richard L Gamelli
Journal:  J Burn Care Rehabil       Date:  2004 Jan-Feb

9.  Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

Authors:  I Viard; P Wehrli; R Bullani; P Schneider; N Holler; D Salomon; T Hunziker; J H Saurat; J Tschopp; L E French
Journal:  Science       Date:  1998-10-16       Impact factor: 47.728

10.  Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy.

Authors:  F Guibal; S Bastuji-Garin; O Chosidow; P Saiag; J Revuz; J C Roujeau
Journal:  Arch Dermatol       Date:  1995-06
View more
  3 in total

Review 1.  [Immunoglobulins in primary antibody deficiency: should they also be used in sepsis and other indications?].

Authors:  S Kluge; G de Heer; A Nierhaus; G Kreymann
Journal:  Internist (Berl)       Date:  2007-11       Impact factor: 0.743

Review 2.  Evidence for the use of intravenous immunoglobulins--a review of the literature.

Authors:  Shaye Kivity; Uriel Katz; Natalie Daniel; Udi Nussinovitch; Neophytos Papageorgiou; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

3.  Are Multimorbidities Underestimated in Scoring Systems of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Like in SCORTEN?

Authors:  Tobias von Wild; Peter L Stollwerck; Thomas Namdar; Felix H Stang; Peter Mailänder; Frank Siemers
Journal:  Eplasty       Date:  2012-08-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.